Trial Profile
A Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Abametapir (Primary)
- Indications Pediculosis
- Focus Registrational; Therapeutic Use
- Sponsors Dr Reddys Laboratories; Hatchtech
- 27 Jul 2020 According to a Dr Reddys Laboratories media release, the U.S. Food and Drug Administration (USFDA) has approved XEGLYZE (abametapir) lotion, 0.74% through a 505(b)(1) NDA.XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
- 14 Sep 2015 According to a Dr. Reddys Laboratories media release dated 14 September 2015, Hatchtech has filed an NDA with the US FDA for Xeglyze (abametapir) lotion.
- 18 Mar 2015 Results published in a Hatchtech media release.